- ►annals.org [PDF] J Seidenfeld, DJ Samson, V Hasselblad, N … - Annals of internal medicine, 2000 - Am Coll Physicians Jerome Seidenfeld, PhD; David J. Samson, BA; Vic Hasselblad, PhD; Naomi Aronson,
PhD; Peter C. Albertsen, MD; Charles L. Bennett, MD, PhD; and Timothy J. Wilt,
MD, MPH ... Purpose: To compare luteinizing hormone–releasing hormone ... Cited by 156 - Related articles - BL Direct - All 7 versions
DJ Samson, J Seidenfeld, B Schmitt, V … - CA A Cancer Journal for Clinicians - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 109 - Related articles - BL Direct - All 3 versions
GJ Bubley - Urology, 2001 - Elsevier Objectives: The existing luteinizing hormone–releasing hormone (LHRH) analogs
have been the preferred method of inducing androgen deprivation for prostate
cancer for over a decade. These agents are well known to cause a surge in ... Cited by 57 - Related articles - BL Direct - All 5 versions
B Schmitt, C Bennett, J Seidenfeld, D Samson, … - Cochrane Database Syst Rev, 2000 - medscape.com All published randomized trials were eligible for inclusion provided they (1)
randomized men with advanced prostate cancer to receive a non – steroidal anti
– androgen (NSAA) medication in addition to castrastion (medical or ... Cited by 54 - Related articles - All 9 versions
- ►oxfordjournals.org AM Bayoumi, AD Brown, AM Garber - JNCI Journal of the National Cancer Institute, 2000 - jnci.oxfordjournals.org Background: The costs and side effects of several antiandrogen therapies for
advanced prostate cancer differ substantially. We estimated the
cost-effectiveness of antiandrogen therapies for advanced prostate cancer. ... Cited by 69 - Related articles - BL Direct - All 8 versions
MG Oefelein, A Feng, MJ Scolieri, D Ricchiutti … - Urology, 2000 - Elsevier Objectives. Based on methods introduced in the late 1960s and no longer used,
serum testosterone level in men after surgical castration was reported to be 50
ng/dL or less. Radioimmunoassay and, subsequently, chemiluminescent methods ... Cited by 64 - Related articles - BL Direct - All 6 versions
J Trachtenberg, M Gittleman, C Steidle, W … - The Journal of urology, 2002 - Elsevier A total of 255 patients were randomized to receive open label 100 mg. abarelix
depot or 7.5 mg. leuprolide acetate intramuscularly injection on days 1, 29, 57,
85, 113 and 141 for 24 weeks. Patients in the abarelix group received an ... Cited by 62 - Related articles - BL Direct - All 4 versions
DP Byar, DK Corle - NCI monographs: a publication of the National Cancer …, 1988 - ncbi.nlm.nih.gov Between 1960 and 1975, the Veterans Administration Cooperative Urological
Research Group conducted a consecutive series of 3 major randomized clinical
trials comparing various endocrine treatments for newly diagnosed prostate ... Cited by 276 - Related articles - All 3 versions
D Mcleod, N Zinner, K Tomera, D Gleason, N … - Urology, 2001 - grande.nal.usda.gov Title: A phase 3, multicenter, open-label, randomized study of abarelix versus
leuprolide acetate in men with prostate cancer. Author: McLeod, D : Zinner, N :
Tomera, K : Gleason, D : Fotheringham, N : Campion, M : Garnick, MB ... Cited by 69 - Related articles - Cached - BL Direct - All 4 versions
P IVERSEN, CJ TYRRELL, AV KAISARY, JB … - The Journal of urology, 2000 - Elsevier A total of 480 patients with locally advanced prostate cancer were randomized to
treatment. After a median followup of 6.3 years mortality was 56%. There was no
statistically significant difference between the 2 groups in overall ... Cited by 232 - Related articles - BL Direct - All 9 versions
